Oncology

QIAGEN provides a portfolio of companion diagnostic assays for determining an individual's mutation status.

Better understanding of the genetic events that underlie tumor development and progression has led to improvements in patient healthcare. Using genetic biomarkers, it is now possible to identify individuals most likely to respond to a particular therapy.

We offer companion diagnostic assays for determining an individual's mutation status.

Choose your biomarker of interest.